Core Viewpoint - The article discusses the recent stock adjustments made by several well-known fund managers, highlighting their changes in holdings in various companies, particularly focusing on Kelong Pharmaceutical and Proya Cosmetics [2]. Group 1: Kelong Pharmaceutical - Fund managers Ge Lan and Tang Xiaobin reduced their holdings in Kelong Pharmaceutical, while Zhao Bei increased her stake [3]. - As of December 31, 2025, Ge Lan's fund held 38.1954 million shares of Kelong Pharmaceutical, a decrease of 1.867 million shares compared to the end of the third quarter [4]. - Tang Xiaobin's fund, Guangfa Multi-Factor Mixed Fund, exited the top ten shareholders of Kelong Pharmaceutical by the end of 2025, having reduced its holdings from 24.2335 million shares to at least 10.2935 million shares [6]. - In contrast, Zhao Bei's fund held 22 million shares of Kelong Pharmaceutical as of December 31, 2025, an increase of 2 million shares from the previous quarter [6]. - The National Social Security Fund's 416 portfolio became the tenth largest shareholder of Kelong Pharmaceutical with 13.9445 million shares by the end of 2025 [7]. Group 2: Proya Cosmetics - Liu Yanchun and Hu Xinwei reduced their holdings in Proya Cosmetics, with Liu's fund holding 2.6 million shares as of December 30, 2025, down from 3.332 million shares [9]. - Hu Xinwei's fund is no longer among the top ten shareholders of Proya Cosmetics [10]. Group 3: Other Companies - Zhou Yun's fund and the National Social Security Fund's 404 portfolio entered the top ten shareholders of Jiazhe New Energy by the end of 2025 [11]. - The National Social Security Fund's 114 portfolio increased its holdings in Nanshan Aluminum by 4.3432 million shares in the fourth quarter of 2025, with five ETF products now included among the top ten shareholders [11]. Group 4: Market Trends - As of early 2026, A-shares stabilized above 4000 points, with over 10,000 institutional research activities focused on sectors like semiconductors and artificial intelligence [13]. - Fund managers express optimism for A-share performance in 2026, anticipating a recovery in earnings growth for non-financial listed companies [13].

每经AI快讯，有投资者在投资者互动平台提问：从近期走势来看是不是公司四季度出现大额亏损？公 司一直在宣传合成生物转型是不是出现了重大问题？ （文章来源：每日经济新闻） 浙江震元（000705.SZ）1月8日在投资者互动平台表示，公司生物定向合成项目S1产线于2025年8月30日 投产，目前结合市场需求逐步释放产能。 ...

Group 1 - The core viewpoint of the article highlights the target price increases for several listed companies, with significant growth percentages noted for众鑫股份, 瑞迈特, and 环旭电子 [1][2] - The companies with the highest target price increases are众鑫股份 (28.45%), 瑞迈特 (20.80%), and 环旭电子 (11.07%), which belong to the packaging printing, medical devices, and consumer electronics industries respectively [1][2] - On January 7, a total of 16 listed companies received broker recommendations, with众鑫股份 receiving recommendations from 2 brokers, while联美控股 and金财互联 received recommendations from 1 broker each [2][4] Group 2 - On January 7, two companies received their first coverage ratings: 联美控股 was rated "增持" (Buy) by 国投证券, and 前沿生物 was rated "推荐" (Recommended) by 国联民生证券 [4][5] - The closing price for众鑫股份 was reported at 77.60 yuan, and it is categorized under the packaging printing industry [4] - The first coverage ratings indicate a positive outlook for both newly covered companies, suggesting potential investment opportunities in the electric power and chemical pharmaceutical sectors [5]

Wind数据显示，1月8日，8家公司共发布8个股票回购相关进展。其中，5家公司披露股票回购实施进 展，3家公司回购方案已实施完毕。 从已完成回购来看，当日共3家公司回购金额超千万。京新药业、华昌达、实朴检测已完成回购金额最 高，分别回购6.09亿元、4189.96万元、3195.12万元。 截至1月8日，今年以来已有29个回购方案已实施完毕，涉及22家公司，其中7家公司已完成回购金额超 亿元。其中京东方A、京新药业、新和成回购金额居前，分别已完成回购15.00亿元、6.09亿元、5.56亿 元。 从回购实施进展来看，健盛集团、东诚药业、民生健康回购金额最高，分别回购1.18亿元、1718.63万 元、1499.93万元。 ...

Core Viewpoint - The company has approved a share repurchase plan aimed at using its own funds to buy back shares for employee stock ownership plans and equity incentives, with a total repurchase amount adjusted to between RMB 35 million and RMB 70 million [2] Group 1: Share Repurchase Plan - The initial share repurchase plan was set for a total amount of no less than RMB 20 million and no more than RMB 40 million, with a maximum repurchase price of RMB 14.80 per share, allowing for an estimated repurchase of approximately 13.51 million to 27.03 million shares [1] - The total repurchase amount was later adjusted to a range of RMB 35 million to RMB 70 million, while other aspects of the repurchase plan remained unchanged [2] - The maximum repurchase price was subsequently adjusted to RMB 14.47 per share, allowing for an estimated repurchase of approximately 24.19 million to 48.38 million shares [3] Group 2: Implementation Status - As of the announcement date, the company completed the share repurchase plan, having repurchased a total of 47.27 million shares, which is 5.49% of the total share capital, with a total expenditure of RMB 608.72 million [4] - The highest purchase price during the repurchase was RMB 14.41 per share, and the lowest was RMB 11.86 per share [4] - The company confirmed that the actual repurchase funds exceeded the lower limit of the initial plan but did not exceed the upper limit, and the repurchase price remained within the set limits [5] Group 3: Compliance and Future Arrangements - The share repurchase was conducted in compliance with relevant regulations, ensuring that no shares were repurchased during periods that could significantly impact stock prices [6] - The repurchased shares will be stored in a dedicated account and will not have voting rights or profit distribution rights during the holding period [7] - If the shares are not utilized for the intended purposes within 36 months, the unused portion will be canceled following legal procedures [7]

Core Viewpoint - The recent announcements from Kelun Pharmaceutical indicate significant changes in institutional holdings, with notable fund managers adjusting their positions, reflecting a mixed sentiment in the market towards the company's future prospects [1] Group 1: Institutional Holdings Changes - Guo Lan, a well-known fund manager from China Europe Fund, reduced holdings in Kelun Pharmaceutical by 1.867 million shares in Q4 2025, following a previous reduction of 2.5371 million shares in Q3 2025 [1] - The Guangfa Multi-Factor Mixed Fund, managed by Tang Xiaobin, also exited the top ten shareholders of Kelun Pharmaceutical by reducing over 10 million shares in Q4 2025 [1] - In contrast, Zhao Bei from ICBC Credit Suisse increased holdings in Kelun Pharmaceutical by 2 million shares in Q4 2025, while the National Social Security Fund's 416 portfolio became a new top ten shareholder with 13.9445 million shares [1] Group 2: Market Sentiment and Future Outlook - Fund managers express optimism about the market, actively seeking investment opportunities, with a focus on sectors like automotive, semiconductors, and specialized equipment [1] - Liu Ankun from Rongtong Fund noted a "short-term active, long-term positive" market characteristic, supported by continuous inflow of incremental funds and strong sectoral performance in AI and non-ferrous metals [1] - The market is expected to continue its upward trend, driven by funding factors and potential catalysts in industries such as semiconductors and commercial aerospace, with a belief that the spring market rally may have already begun [1]

Group 1 - Kelong Pharmaceutical has seen a reduction in holdings by the China Europe Medical Health Mixed Fund managed by fund manager Ge Lan, from 42.60 million shares at the end of Q2 2025 to 38.20 million shares by the end of Q4 2025, indicating a decrease of 1.87 million shares [1] - The same fund had already begun reducing its stake in Kelong Pharmaceutical in Q3 2025, where the holdings decreased from 42.60 million shares to 40.06 million shares, a reduction of 2.53 million shares [1] - In contrast, the Industrial Bank of China Credit Suisse Frontier Medical Stock Fund managed by Zhao Bei increased its holdings in Kelong Pharmaceutical from 20.00 million shares at the end of Q3 2025 to 22.00 million shares by the end of Q4 2025 [1] Group 2 - Proya, another well-known consumer goods company, announced a share buyback on January 5, 2025, revealing that the Invesco Great Wall Emerging Growth Mixed Fund managed by Liu Yanchun reduced its holdings from 3.33 million shares at the end of Q3 2025 to 2.60 million shares by the end of December 30, 2025, a decrease of over 700,000 shares [2] - Additionally, the fund managed by Hu Xinwei, the Huatai-PineBridge Consumer Industry Mixed Fund, has exited the top ten circulating shareholders of Proya [2]

证券日报网讯 1月7日，华仁药业在互动平台回答投资者提问时表示，股价受多方面因素影响，公司非 常重视股价表现，并通过企业内生增长和外延并购推动主营业务快速稳定发展。公司2025年经营情况将 于2025年年度报告中披露。 （编辑 丛可心） ...

证券日报网讯 1月7日，海昇药业发布公告称，公司使用闲置募集资金2.55亿元购买杭州银行"添利宝"结 构性存款，期限25天，预计年化收益0.45%至2.45%，截至公告日尚未到期理财产品余额2.55亿元，占 2024年经审计净资产39.07%。 （文章来源：证券日报） ...

Core Viewpoint - Huadong Medicine's Biomee®1 and Biomee®2 creams are not yet launched overseas and will be registered as imported cosmetics in China, bypassing the drug approval process and clinical trials [1] Group 1 - The products Biomee®1 and Biomee®2 are currently not available in international markets [1] - The registration process for these products in China will follow the imported cosmetics pathway rather than the drug registration approval route [1] - This approach allows the company to avoid the need for conducting clinical trials domestically [1]